Ginkgo Bioworks Holdings Cash Flow Conversion Efficiency
Ginkgo Bioworks Holdings cash flow conversion efficiency. Based on the latest financial reports, Ginkgo Bioworks Holdings (DNA) has a cash flow conversion efficiency ratio of -0.105x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-44.27 Million) by net assets ($420.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ginkgo Bioworks Holdings (2019–2025)
Cash flow conversion efficiency of Ginkgo Bioworks Holdings from 2019 to 2025. This chart illustrates how Ginkgo Bioworks Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Ginkgo Bioworks Holdings for real-time trading data and today's change.
Ginkgo Bioworks Holdings Cash Flow Conversion Ratio Explained
Ginkgo Bioworks Holdings cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ginkgo Bioworks Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ginkgo Bioworks Holdings ranked by their cash flow conversion efficiency. Also see Ginkgo Bioworks Holdings market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kid ASA
OL:KID
|
0.155x |
|
Rogers Sugar Inc.
TO:RSI
|
0.099x |
|
VP Bank AG
F:3VFN
|
0.130x |
|
Siantar Top Tbk
JK:STTP
|
0.042x |
|
Beijing SDL Technology Co Ltd
SHE:002658
|
0.056x |
|
Thunder Tiger Corp
TW:8033
|
-0.014x |
|
Warteck Invest Ltd
SW:WARN
|
0.021x |
|
Chengdu Xiling Power Science & Technology Incorporated Co Class A
SHE:300733
|
0.070x |
Annual Cash Flow Conversion Efficiency for Ginkgo Bioworks Holdings (2019–2025)
The table below shows the annual cash flow conversion efficiency of Ginkgo Bioworks Holdings from 2019 to 2025. Review DNA FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $508.59 Million | $-171.06 Million | -0.336x | +24.64% |
| 2024-12-31 | $716.06 Million | $-319.58 Million | -0.446x | -65.71% |
| 2023-12-31 | $1.10 Billion | $-295.50 Million | -0.269x | -85.42% |
| 2022-12-31 | $1.74 Billion | $-252.20 Million | -0.145x | +10.30% |
| 2021-12-31 | $1.57 Billion | $-253.82 Million | -0.162x | +43.96% |
| 2020-12-31 | $470.05 Million | $-135.83 Million | -0.289x | -224.70% |
| 2019-12-31 | $501.85 Million | $-44.66 Million | -0.089x | -- |
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artific… Read more